<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076112</url>
  </required_header>
  <id_info>
    <org_study_id>B-1612/375-004</org_study_id>
    <nct_id>NCT03076112</nct_id>
  </id_info>
  <brief_title>Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin</brief_title>
  <official_title>Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on
      glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus,
      whose HbA1c level is ≥ 7.5% with sulfonylurea and metformin, 2) to investigate changes of
      other metabolic and cardiovascular risk factors such as triglyceride, HDL-cholesterol, uric
      acid, blood pressure, and inflammatory markers, 3) to examine changes of body composition
      including fat and muscle mass with volume status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of HbA1c after 24 weeks' treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic target goal achievement</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Glycemic target goal achievement (HbA1c &lt; 7%) at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of body weight at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat mass</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>Change of body fat mass at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose level</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of fasting plasma glucose level at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial 2hr glucose level</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Changes of postprandial 2hr glucose level at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Change of systolic/diastolic blood pressure at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride/HDL-cholesterol ratio</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Changes of triglyceride/HDL-cholesterol ratio at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Changes of uric acid at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Changes of parathyroid hormone at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-hydroxyvitamin D</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>Changes of 25-hydroxyvitamin D at week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ipragliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin
** Metformin and sulfonylurea's dosages
Metformin 500 mg ‒ 2550 mg
Sulfonylurea: Glimepiride 1 mg ‒ 8 mg or Gliclazide MR 30 mg ‒ 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin
** Metformin and sulfonylurea's dosages
Metformin 500 mg ‒ 2550 mg
Sulfonylurea: Glimepiride 1 mg ‒ 8 mg or Gliclazide MR 30 mg ‒ 120 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipragliflozin</intervention_name>
    <description>Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes</description>
    <arm_group_label>Ipragliflozin</arm_group_label>
    <other_name>Suglat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with HbA1c 7.5% - 9.0% at screening visit

          -  Male or female between 20 and 75 years of age

          -  Patients taking sulfonylurea (glimepiride 1~8mg or gliclazide 30~120 mg or equivalent
             dose) and metformin (≥ 1000 mg or maximum tolerated dose) for more than 3 months

          -  BMI ≥23 kg/m²

          -  Estimated GFR ≥ 60 ml/min/1.73m²

          -  Women of child bearing potential must take precautions to avoid pregnancy throughout
             the study and for 4 weeks after intake of the last dose and must have a negative
             urinary pregnancy test.

        Exclusion Criteria:

          -  Type 1 diabetes, gestational diabetes, or diabetes with secondary cause

          -  Patients with acute coronary syndrome within 3 months prior to screening visit

          -  Patients with acute coronary syndrome within 3 months prior to screening visit

          -  Pregnant or breastfeeding women or reproductive-age women who refuse contraception

          -  Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT &gt;
             3-fold the upper limit of normal)

          -  Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer
             with appropriate treatment) except thyroid cancer or carcinoma in situ

          -  Other clinical trials within 30 days

          -  Alcohol abuse

          -  Contraindication to SGLT2 inhibitors or Dipeptidyl-peptidase 4 inhibitors

          -  Taking insulin, oral hypoglycemic agents other than metformin, sulfonylurea, and the
             study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie-Eun Lee, MD</last_name>
    <phone>+82-10-7178-1569</phone>
    <email>orangerie@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo Lim, MD, PhD</last_name>
    <phone>+82-31-787-7035</phone>
    <email>limsoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Lim, MD, PHD</last_name>
      <phone>82-31-787-7035</phone>
      <email>limsoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kyoung Min Kim, MD, PHD</last_name>
      <phone>82-31-787-7047</phone>
      <email>kyoungmin02@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Soo Lim, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Hedrington MS, Davis SN. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):613-23. doi: 10.1517/17425255.2015.1009893. Epub 2015 Feb 2. Review.</citation>
    <PMID>25643044</PMID>
  </reference>
  <reference>
    <citation>Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, Nakajo I, Smulders R. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014 Nov;53(11):975-88. doi: 10.1007/s40262-014-0180-z. Review.</citation>
    <PMID>25316572</PMID>
  </reference>
  <reference>
    <citation>Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012 Aug;34(8):1761-71. doi: 10.1016/j.clinthera.2012.06.027. Epub 2012 Jul 15.</citation>
    <PMID>22795925</PMID>
  </reference>
  <reference>
    <citation>Takasu T, Hayashizaki Y, Tahara A, Kurosaki E, Takakura S. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. Clin Exp Pharmacol Physiol. 2015 Jan;42(1):87-93. doi: 10.1111/1440-1681.12317.</citation>
    <PMID>25311502</PMID>
  </reference>
  <reference>
    <citation>Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012 Oct;14(10):937-43. doi: 10.1111/j.1463-1326.2012.01624.x. Epub 2012 Jun 7.</citation>
    <PMID>22587345</PMID>
  </reference>
  <reference>
    <citation>Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, Poucher SM. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. doi: 10.1111/j.1463-1326.2010.01291.x.</citation>
    <PMID>20880347</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29.</citation>
    <PMID>23906445</PMID>
  </reference>
  <reference>
    <citation>Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S; Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666. Epub 2015 Jan 15.</citation>
    <PMID>25592197</PMID>
  </reference>
  <reference>
    <citation>Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.</citation>
    <PMID>17593236</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ipragliflozin</keyword>
  <keyword>Sitagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

